To assess GPx4 expression as a possible contributor to oxytosis/ferroptosis sensitivity in NPC, Western blot analyses were conducted using dermal fibroblasts from NPC patients and controls following treatment with 100 nM RSL3 at 2, 4, and 8 h timepoints. This evidence concerns the gene GPX4 and nasopharyngeal carcinoma.